Cargando…

GCT-12. SIOP CNS GCT II: High Risk (HR) CNS Non-germinomatous Germ Cell Tumours (NGGCT) treated with Dose intensified PEI – final results

Based on results of SIOP CNS GCT 96, patients enrolled in SIOP CNS GCT II with AFP higher or 1000 ng/ml (serum and/or CSF) and/or age less than 6 years with NGGCTs at diagnosis received two standard cycles of PEI and two higher dose PEI courses followed by radiotherapy according to dissemination (54...

Descripción completa

Detalles Bibliográficos
Autores principales: Calaminus, Gabriele, Frappaz, Didier, Ajithkumar, Thankamma, Müller, Jans-Enno, Zimmermann, Martin, Conter, Cecile Faure, Timmermann, Beate, Alapetite, Claire, Murray, Matthew, Garre, Maria Luisa, Dieckmann, Karin, Peyrl, Andreas, Gerber, Nicolas U, Kortmann, Rolf-Dieter, Nicholson, James
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164857/
http://dx.doi.org/10.1093/neuonc/noac079.206
_version_ 1784720244055474176
author Calaminus, Gabriele
Frappaz, Didier
Ajithkumar, Thankamma
Müller, Jans-Enno
Zimmermann, Martin
Conter, Cecile Faure
Timmermann, Beate
Alapetite, Claire
Murray, Matthew
Garre, Maria Luisa
Dieckmann, Karin
Peyrl, Andreas
Gerber, Nicolas U
Kortmann, Rolf-Dieter
Nicholson, James
author_facet Calaminus, Gabriele
Frappaz, Didier
Ajithkumar, Thankamma
Müller, Jans-Enno
Zimmermann, Martin
Conter, Cecile Faure
Timmermann, Beate
Alapetite, Claire
Murray, Matthew
Garre, Maria Luisa
Dieckmann, Karin
Peyrl, Andreas
Gerber, Nicolas U
Kortmann, Rolf-Dieter
Nicholson, James
author_sort Calaminus, Gabriele
collection PubMed
description Based on results of SIOP CNS GCT 96, patients enrolled in SIOP CNS GCT II with AFP higher or 1000 ng/ml (serum and/or CSF) and/or age less than 6 years with NGGCTs at diagnosis received two standard cycles of PEI and two higher dose PEI courses followed by radiotherapy according to dissemination (54 Gy local RT or 30 Gy CSI/24 Gy tumour boost). Between 2/2012 and 7/2018, 112 patients with CNS NGGCT were registered, of whom 23 were identified as HR patients; 18/23 had an AFP higher or 1000 ng/ml and were older than 6 years. Five children were < 6 years and showed YST elements in histology. of whom 3 received chemotherapy alone due to age. Primary site was pineal in 15/23, suprasellar in 5/23, bifocal in 3/23 patients; 3/23 patients were metastatic at diagnosis and 9/23 patients relapsed. Three years EFS was 0.60±0.10 with a median observation time of 3.96 years. Two recurrences were local, 4 distant (metastatic) and 3 combined, local and distant. HR CNS NGGCTs appeared to benefit from dose intensified PEI, compared with those treated in SIOP CNS GCT 96 with standard dose PEI. These results support the further exploration of this chemotherapy regimen in future clinical trials in such patient groups, including the consideration of delivering three dose intensified courses after one standard chemotherapy course, as is the practice in some groups treating very high risk extracranial GCTs.
format Online
Article
Text
id pubmed-9164857
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-91648572022-06-05 GCT-12. SIOP CNS GCT II: High Risk (HR) CNS Non-germinomatous Germ Cell Tumours (NGGCT) treated with Dose intensified PEI – final results Calaminus, Gabriele Frappaz, Didier Ajithkumar, Thankamma Müller, Jans-Enno Zimmermann, Martin Conter, Cecile Faure Timmermann, Beate Alapetite, Claire Murray, Matthew Garre, Maria Luisa Dieckmann, Karin Peyrl, Andreas Gerber, Nicolas U Kortmann, Rolf-Dieter Nicholson, James Neuro Oncol Germ Cell Tumors Based on results of SIOP CNS GCT 96, patients enrolled in SIOP CNS GCT II with AFP higher or 1000 ng/ml (serum and/or CSF) and/or age less than 6 years with NGGCTs at diagnosis received two standard cycles of PEI and two higher dose PEI courses followed by radiotherapy according to dissemination (54 Gy local RT or 30 Gy CSI/24 Gy tumour boost). Between 2/2012 and 7/2018, 112 patients with CNS NGGCT were registered, of whom 23 were identified as HR patients; 18/23 had an AFP higher or 1000 ng/ml and were older than 6 years. Five children were < 6 years and showed YST elements in histology. of whom 3 received chemotherapy alone due to age. Primary site was pineal in 15/23, suprasellar in 5/23, bifocal in 3/23 patients; 3/23 patients were metastatic at diagnosis and 9/23 patients relapsed. Three years EFS was 0.60±0.10 with a median observation time of 3.96 years. Two recurrences were local, 4 distant (metastatic) and 3 combined, local and distant. HR CNS NGGCTs appeared to benefit from dose intensified PEI, compared with those treated in SIOP CNS GCT 96 with standard dose PEI. These results support the further exploration of this chemotherapy regimen in future clinical trials in such patient groups, including the consideration of delivering three dose intensified courses after one standard chemotherapy course, as is the practice in some groups treating very high risk extracranial GCTs. Oxford University Press 2022-06-03 /pmc/articles/PMC9164857/ http://dx.doi.org/10.1093/neuonc/noac079.206 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Germ Cell Tumors
Calaminus, Gabriele
Frappaz, Didier
Ajithkumar, Thankamma
Müller, Jans-Enno
Zimmermann, Martin
Conter, Cecile Faure
Timmermann, Beate
Alapetite, Claire
Murray, Matthew
Garre, Maria Luisa
Dieckmann, Karin
Peyrl, Andreas
Gerber, Nicolas U
Kortmann, Rolf-Dieter
Nicholson, James
GCT-12. SIOP CNS GCT II: High Risk (HR) CNS Non-germinomatous Germ Cell Tumours (NGGCT) treated with Dose intensified PEI – final results
title GCT-12. SIOP CNS GCT II: High Risk (HR) CNS Non-germinomatous Germ Cell Tumours (NGGCT) treated with Dose intensified PEI – final results
title_full GCT-12. SIOP CNS GCT II: High Risk (HR) CNS Non-germinomatous Germ Cell Tumours (NGGCT) treated with Dose intensified PEI – final results
title_fullStr GCT-12. SIOP CNS GCT II: High Risk (HR) CNS Non-germinomatous Germ Cell Tumours (NGGCT) treated with Dose intensified PEI – final results
title_full_unstemmed GCT-12. SIOP CNS GCT II: High Risk (HR) CNS Non-germinomatous Germ Cell Tumours (NGGCT) treated with Dose intensified PEI – final results
title_short GCT-12. SIOP CNS GCT II: High Risk (HR) CNS Non-germinomatous Germ Cell Tumours (NGGCT) treated with Dose intensified PEI – final results
title_sort gct-12. siop cns gct ii: high risk (hr) cns non-germinomatous germ cell tumours (nggct) treated with dose intensified pei – final results
topic Germ Cell Tumors
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164857/
http://dx.doi.org/10.1093/neuonc/noac079.206
work_keys_str_mv AT calaminusgabriele gct12siopcnsgctiihighriskhrcnsnongerminomatousgermcelltumoursnggcttreatedwithdoseintensifiedpeifinalresults
AT frappazdidier gct12siopcnsgctiihighriskhrcnsnongerminomatousgermcelltumoursnggcttreatedwithdoseintensifiedpeifinalresults
AT ajithkumarthankamma gct12siopcnsgctiihighriskhrcnsnongerminomatousgermcelltumoursnggcttreatedwithdoseintensifiedpeifinalresults
AT mullerjansenno gct12siopcnsgctiihighriskhrcnsnongerminomatousgermcelltumoursnggcttreatedwithdoseintensifiedpeifinalresults
AT zimmermannmartin gct12siopcnsgctiihighriskhrcnsnongerminomatousgermcelltumoursnggcttreatedwithdoseintensifiedpeifinalresults
AT contercecilefaure gct12siopcnsgctiihighriskhrcnsnongerminomatousgermcelltumoursnggcttreatedwithdoseintensifiedpeifinalresults
AT timmermannbeate gct12siopcnsgctiihighriskhrcnsnongerminomatousgermcelltumoursnggcttreatedwithdoseintensifiedpeifinalresults
AT alapetiteclaire gct12siopcnsgctiihighriskhrcnsnongerminomatousgermcelltumoursnggcttreatedwithdoseintensifiedpeifinalresults
AT murraymatthew gct12siopcnsgctiihighriskhrcnsnongerminomatousgermcelltumoursnggcttreatedwithdoseintensifiedpeifinalresults
AT garremarialuisa gct12siopcnsgctiihighriskhrcnsnongerminomatousgermcelltumoursnggcttreatedwithdoseintensifiedpeifinalresults
AT dieckmannkarin gct12siopcnsgctiihighriskhrcnsnongerminomatousgermcelltumoursnggcttreatedwithdoseintensifiedpeifinalresults
AT peyrlandreas gct12siopcnsgctiihighriskhrcnsnongerminomatousgermcelltumoursnggcttreatedwithdoseintensifiedpeifinalresults
AT gerbernicolasu gct12siopcnsgctiihighriskhrcnsnongerminomatousgermcelltumoursnggcttreatedwithdoseintensifiedpeifinalresults
AT kortmannrolfdieter gct12siopcnsgctiihighriskhrcnsnongerminomatousgermcelltumoursnggcttreatedwithdoseintensifiedpeifinalresults
AT nicholsonjames gct12siopcnsgctiihighriskhrcnsnongerminomatousgermcelltumoursnggcttreatedwithdoseintensifiedpeifinalresults